SG11201804594YA - L-valinate of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof - Google Patents
L-valinate of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereofInfo
- Publication number
- SG11201804594YA SG11201804594YA SG11201804594YA SG11201804594YA SG11201804594YA SG 11201804594Y A SG11201804594Y A SG 11201804594YA SG 11201804594Y A SG11201804594Y A SG 11201804594YA SG 11201804594Y A SG11201804594Y A SG 11201804594YA SG 11201804594Y A SG11201804594Y A SG 11201804594YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- genove
- valinate
- january
- hydroxypropylthiazolidine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Cephalosporin Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrrole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Emergency Medicine (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -' Organization International Bureau res:0) (43) International Publication Date .... ....r .....) 13 July 2017 (13.07.2017) WI P0 I P CT (10) WO International 1111111111113111111111111111111111111111111111111111111111111111111111111111111111111111 2017/118641 Publication Number Al (51) International Patent Classification: SCHWARZ, Matthias; 43, Rue Philippe Plantamour, C07D 277/06 (2006.01) A61P 15/00 (2006.01) 1201 GenOve (CH). JORAND-LEBRUN, Catherine; A61K 31/426 (2006.01) A61P 15/06 (2006.01) Chef Lieu, 74270 Contamine-Sarzin (FR). QUATTRO- A61K 45/06 (2006.01) PANI, Anna; Rte de Cherie 2, 1207 GenOve (CH). POMEL, Vincent; 228, Chemin du Bois des Presses, (21) International Application Number: PCT/EP2017/050101 74570 Groisy (FR). (74) Agent: KATZAROV S.A.; 19 rue des Epinettes, 1227 (22) International Filing Date: GenOve (CH). 4 January 2017 (04.01.2017) (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (26) Publication Language: English AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (30) Priority Data: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, 14/987,586 4 January 2016 (04.01.2016) US HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, ICH, KN, 62/274,674 4 January 2016 (04.01.2016) US KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, 62/395,664 16 September 2016 (16.09.2016) US MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, 62/407,918 13 October 2016 (13.10.2016) US NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (71) Applicant: MERCK SERONO S.A. [CH/CH]; Centre In- RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, dustriel, 1267 Coinsins (CH). TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (72) Inventors: NAXOS PAGE, Patrick; Les Cyclades, Aven- ue de GenOve, 74160 Saint-Julien-en-Genevois (CH). [Continued on next page] (54) Title: L-VALINATE OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF (57) : The invention the L- provides valinate ester of a hydroxypropylthiazolidine ( I) F derivative formula carboxamide of (I), (2S)- 3-([1,1'-biphenyl]-4-ylsulfony1)-N-[(1S)-3- hydroxy-1- phenylpropy1]-1,3-thiazolidine-2- 0 carboxamide, as well as salts and crystal cA , poly- ip...Nh, s sm morphs thereof. The compound inhibits the ‘\") 4 11 F receptor (PGF2alpha) and is a prostaglandin useful the treatment of such as Irl in disorders preterm labor at the early gestational stage or FIG. 1 dysmennorrhea. 4 -.:-.c.-,=.:.= Il .4t Il - P-- W - .4 Gni - veins)) -- 4\" - Atzwianat i t 4 Ott - $siR$tit4 . , 1 3 3 tan x initash, rn Il it--- , pel i'M lz ves4de-rckinf& p.m 11 C ei O WO 2017/118641 Al MMEDIMOMOIDEIRMEM3011111011001VOIRVOIS (84) Designated States (unless otherwise indicated, for every SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, kind of regional protection available): ARIPO (BW, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, GH, SZ, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, Published: RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, CZ, IT, RS, DE, — LT, SE, with international search report (Art. 21(3))
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662274674P | 2016-01-04 | 2016-01-04 | |
| US14/987,586 US9447055B1 (en) | 2016-01-04 | 2016-01-04 | α-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof |
| US201662395664P | 2016-09-16 | 2016-09-16 | |
| US201662407918P | 2016-10-13 | 2016-10-13 | |
| PCT/EP2017/050101 WO2017118641A1 (en) | 2016-01-04 | 2017-01-04 | L-valinate of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201804594YA true SG11201804594YA (en) | 2018-06-28 |
Family
ID=57799697
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201804789QA SG11201804789QA (en) | 2016-01-04 | 2017-01-04 | Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof |
| SG11201804594YA SG11201804594YA (en) | 2016-01-04 | 2017-01-04 | L-valinate of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof |
| SG10202009723PA SG10202009723PA (en) | 2016-01-04 | 2017-01-04 | Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof |
| SG10202009769WA SG10202009769WA (en) | 2016-01-04 | 2017-01-04 | L-valinate of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201804789QA SG11201804789QA (en) | 2016-01-04 | 2017-01-04 | Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202009723PA SG10202009723PA (en) | 2016-01-04 | 2017-01-04 | Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof |
| SG10202009769WA SG10202009769WA (en) | 2016-01-04 | 2017-01-04 | L-valinate of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof |
Country Status (23)
| Country | Link |
|---|---|
| EP (4) | EP4140988A1 (en) |
| JP (5) | JP6933322B2 (en) |
| KR (2) | KR20180100120A (en) |
| CN (1) | CN108779087A (en) |
| AU (4) | AU2017205254B2 (en) |
| CA (2) | CA3009576A1 (en) |
| DK (2) | DK3397622T3 (en) |
| EA (1) | EA036990B1 (en) |
| ES (2) | ES2915948T3 (en) |
| HR (2) | HRP20220673T1 (en) |
| HU (2) | HUE058871T2 (en) |
| IL (4) | IL284912B (en) |
| LT (2) | LT3397622T (en) |
| MA (2) | MA43580A (en) |
| MX (3) | MX2018008157A (en) |
| PL (2) | PL3397622T3 (en) |
| PT (2) | PT3397622T (en) |
| RS (2) | RS63286B1 (en) |
| SG (4) | SG11201804789QA (en) |
| SI (2) | SI3397622T1 (en) |
| UA (2) | UA125377C2 (en) |
| WO (2) | WO2017118641A1 (en) |
| ZA (1) | ZA201903769B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201804789QA (en) * | 2016-01-04 | 2018-07-30 | ObsEva SA | Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof |
| RU2711615C1 (en) * | 2019-09-12 | 2020-01-17 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт акушерства, гинекологии и репродуктологии имени Д.О. Отта" | Method of endometriosis treatment based on an experimental model in rats |
| EP4034129A4 (en) * | 2019-09-23 | 2023-11-01 | The Board of Trustees of the Leland Stanford Junior University | Methods of treatments to prolong gestation and complications of menstruation or gestation |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3835175A (en) | 1971-03-15 | 1974-09-10 | Research Corp | 9-fluorenylmethanol haloformates, carbonates and thiocarbonates |
| US3839396A (en) | 1971-07-15 | 1974-10-01 | Shionogi & Co | 9-lower alkyl-9-fluorenyl carbonates |
| US4108846A (en) | 1977-02-01 | 1978-08-22 | Hoffmann-La Roche Inc. | Solid phase synthesis with base N alpha-protecting group cleavage |
| SE430885B (en) | 1980-03-24 | 1983-12-19 | Ferring Ab | OXYTOCIN DERIVATIVES |
| US4581167A (en) | 1982-01-19 | 1986-04-08 | Research Corporation | Peptide synthesis and amino acid blocking agents |
| US4508657A (en) | 1982-01-19 | 1985-04-02 | Research Corporation | Peptide synthesis and amino acid blocking agents |
| EP0112809B1 (en) | 1982-12-21 | 1986-05-28 | Ferring AB | Vasotocin derivatives |
| US4460501A (en) | 1983-08-30 | 1984-07-17 | Research Corporation | Process for the synthesis of peptides utilizing thioxanthylmethyloxycarbonyl dioxides |
| US5370135A (en) * | 1993-10-13 | 1994-12-06 | Biex, Inc. | Use of estriol measurement to monitor tocolytic therapy |
| DE4434488A1 (en) * | 1994-09-14 | 1996-03-21 | Schering Ag | Steroid esters and amides, processes for their preparation and their pharmaceutical use |
| SE9604341D0 (en) | 1996-11-26 | 1996-11-26 | Ferring Bv | Hepta-peptide oxytocin analogue |
| IN188411B (en) * | 1997-03-27 | 2002-09-21 | Yuhan Corp | |
| CA2410655A1 (en) * | 2000-05-30 | 2001-12-06 | John H. Dodd | Dihydropyridine compounds for the inhibition of calcium-influx |
| GB0130677D0 (en) | 2001-12-21 | 2002-02-06 | Glaxo Group Ltd | Medicaments and novel compounds |
| JP4615221B2 (en) | 2002-02-27 | 2011-01-19 | フェリング ベスローテン フェンノートシャップ | Intermediates and methods for producing heptapeptide oxytocin analogs |
| JP4602672B2 (en) * | 2002-03-28 | 2010-12-22 | メルク セローノ ソシエテ アノニム | Thiazolidinecarboxamide derivatives as modulators of prostaglandin F receptors |
| GB0208785D0 (en) * | 2002-04-17 | 2002-05-29 | Medical Res Council | Treatment methtods |
| US7521530B2 (en) * | 2002-06-11 | 2009-04-21 | Universite De Montreal | Peptides and peptidomimetics useful for inhibiting the activity of prostaglandin F2α receptor |
| UA78058C2 (en) | 2002-07-05 | 2007-02-15 | Applied Research Systems | Pyrrolidine derivative as oxitocin antagonists |
| ES2470771T3 (en) * | 2002-12-12 | 2014-06-24 | Idenix Pharmaceuticals, Inc | Procedure for the production of branched nucleosides in 2 ' |
| GB0314738D0 (en) | 2003-06-24 | 2003-07-30 | Glaxo Group Ltd | Novel compounds |
| GB0414093D0 (en) | 2004-06-23 | 2004-07-28 | Glaxo Group Ltd | Novel compounds |
| US8716286B2 (en) | 2009-10-30 | 2014-05-06 | Glaxo Group Limited | Crystalline forms of (3R, 6R)-3-(2,3-dihydro-1H-inden-2-yl)-1-[(1R)-1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1S)-1-methylpropyl]-2,5-piperazinedione |
| EP2845850A1 (en) | 2013-09-10 | 2015-03-11 | ObsEva S.A. | Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists |
| EP2886107A1 (en) | 2013-12-17 | 2015-06-24 | ObsEva S.A. | Oral formulations of pyrrolydine derivatives |
| CA2952585A1 (en) * | 2014-06-16 | 2015-12-23 | Glaxosmithkline Intellectual Property Development Limited | Retosiban for the treatment of pre-term labour |
| JP2017519015A (en) | 2014-07-02 | 2017-07-13 | オブセヴァ エス．エー． | Crystalline (3Z, 5S) -5- (hydroxymethyl) -1-[(2'-methyl-1,1'-biphenyl-4-yl) useful in methods for treating diseases related to OT-R activity ) Carbonyl] pyrrolidin-3-one О-methyloxime |
| ES2716862T3 (en) | 2014-12-22 | 2019-06-17 | Ferring Bv | Therapy with oxytocin receptor antagonists in the luteal phase for implantation and pregnancy in women undergoing assisted reproduction technologies |
| US9447055B1 (en) * | 2016-01-04 | 2016-09-20 | Merck Serono S.A. | α-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof |
| SG11201804789QA (en) * | 2016-01-04 | 2018-07-30 | ObsEva SA | Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof |
-
2017
- 2017-01-04 SG SG11201804789QA patent/SG11201804789QA/en unknown
- 2017-01-04 PT PT177003910T patent/PT3397622T/en unknown
- 2017-01-04 AU AU2017205254A patent/AU2017205254B2/en active Active
- 2017-01-04 SG SG11201804594YA patent/SG11201804594YA/en unknown
- 2017-01-04 PL PL17700391T patent/PL3397622T3/en unknown
- 2017-01-04 UA UAA201806074A patent/UA125377C2/en unknown
- 2017-01-04 PT PT177003928T patent/PT3400217T/en unknown
- 2017-01-04 LT LTEPPCT/EP2017/050099T patent/LT3397622T/en unknown
- 2017-01-04 RS RS20220548A patent/RS63286B1/en unknown
- 2017-01-04 JP JP2018529634A patent/JP6933322B2/en active Active
- 2017-01-04 MX MX2018008157A patent/MX2018008157A/en unknown
- 2017-01-04 SI SI201731162T patent/SI3397622T1/en unknown
- 2017-01-04 EP EP22152238.6A patent/EP4140988A1/en active Pending
- 2017-01-04 HR HRP20220673TT patent/HRP20220673T1/en unknown
- 2017-01-04 SG SG10202009723PA patent/SG10202009723PA/en unknown
- 2017-01-04 SI SI201731161T patent/SI3400217T1/en unknown
- 2017-01-04 CA CA3009576A patent/CA3009576A1/en active Pending
- 2017-01-04 DK DK17700391.0T patent/DK3397622T3/en active
- 2017-01-04 HU HUE17700392A patent/HUE058871T2/en unknown
- 2017-01-04 EP EP22153566.9A patent/EP4144351A1/en active Pending
- 2017-01-04 CN CN201780015011.9A patent/CN108779087A/en active Pending
- 2017-01-04 HU HUE17700391A patent/HUE058872T2/en unknown
- 2017-01-04 RS RS20220547A patent/RS63285B1/en unknown
- 2017-01-04 ES ES17700391T patent/ES2915948T3/en active Active
- 2017-01-04 CA CA3009573A patent/CA3009573A1/en active Pending
- 2017-01-04 KR KR1020187018312A patent/KR20180100120A/en not_active Application Discontinuation
- 2017-01-04 SG SG10202009769WA patent/SG10202009769WA/en unknown
- 2017-01-04 LT LTEPPCT/EP2017/050101T patent/LT3400217T/en unknown
- 2017-01-04 EP EP17700392.8A patent/EP3400217B1/en active Active
- 2017-01-04 JP JP2018529284A patent/JP7169573B2/en active Active
- 2017-01-04 AU AU2017205670A patent/AU2017205670B2/en active Active
- 2017-01-04 MA MA043580A patent/MA43580A/en unknown
- 2017-01-04 IL IL284912A patent/IL284912B/en unknown
- 2017-01-04 ES ES17700392T patent/ES2916835T3/en active Active
- 2017-01-04 MX MX2018008304A patent/MX2018008304A/en unknown
- 2017-01-04 MA MA043549A patent/MA43549A/en unknown
- 2017-01-04 DK DK17700392.8T patent/DK3400217T3/en active
- 2017-01-04 EA EA201891095A patent/EA036990B1/en unknown
- 2017-01-04 PL PL17700392T patent/PL3400217T3/en unknown
- 2017-01-04 WO PCT/EP2017/050101 patent/WO2017118641A1/en active Application Filing
- 2017-01-04 KR KR1020187018929A patent/KR20180099708A/en not_active Application Discontinuation
- 2017-01-04 HR HRP20220674TT patent/HRP20220674T1/en unknown
- 2017-01-04 EP EP17700391.0A patent/EP3397622B1/en active Active
- 2017-01-04 UA UAA201806830A patent/UA125118C2/en unknown
- 2017-01-04 WO PCT/EP2017/050099 patent/WO2017118639A1/en active Application Filing
-
2018
- 2018-05-31 IL IL259742A patent/IL259742B/en unknown
- 2018-06-26 IL IL260286A patent/IL260286B/en unknown
- 2018-06-29 MX MX2022000154A patent/MX2022000154A/en unknown
-
2019
- 2019-05-24 ZA ZA2019/03769A patent/ZA201903769B/en unknown
-
2021
- 2021-08-05 JP JP2021129297A patent/JP7432284B2/en active Active
- 2021-08-16 AU AU2021218009A patent/AU2021218009B2/en active Active
- 2021-12-22 IL IL289256A patent/IL289256A/en unknown
-
2022
- 2022-10-18 JP JP2022166814A patent/JP7377588B2/en active Active
-
2023
- 2023-09-21 AU AU2023233151A patent/AU2023233151A1/en active Pending
- 2023-10-25 JP JP2023183345A patent/JP2024012376A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201810683VA (en) | Process for preparing n-(5-(3-(7-(3-fluorophenyl)-3h-imidazo[4,5-c]pyridin-2-yl)-1h-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide | |
| SG11201906134YA (en) | Tyrosine amide derivatives as rho- kinase inhibitors | |
| SG11201908598PA (en) | Compounds useful in the treatment or prevention of a prmt5-mediated disorder | |
| SG11201903487SA (en) | PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF | |
| SG11201808582RA (en) | Pyrrolotriazine compounds as tam inhibitors | |
| SG11201806745RA (en) | Sulfonylureas and related compounds and use of same | |
| SG11201903144PA (en) | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors | |
| SG11201901700UA (en) | Biaryl compounds useful as immunomodulators | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201807301SA (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
| SG11201804098TA (en) | Purinones as ubiquitin-specific protease 1 inhibitors | |
| SG11201808878UA (en) | Heterocyclic compounds as ret kinase inhibitors | |
| SG11201811491YA (en) | Quinazoline and indole compounds to treat medical disorders | |
| SG11201810579YA (en) | Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders | |
| SG11201908640TA (en) | Pyrrolidinones and a process to prepare them | |
| SG11201804373VA (en) | Compositions and methods for immunooncology | |
| SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
| SG11201808108XA (en) | Synthesis of indazoles | |
| SG11201805387RA (en) | Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201901850XA (en) | Dopamine-b-hydroxylase inhibitors | |
| SG11201408641UA (en) | Phenoxyethyl piperidine compounds | |
| SG11201907774VA (en) | Sulfoximine glycosidase inhibitors | |
| SG11201804587QA (en) | Isoindole compounds |